Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV103 cohort K. O'Donnell, P. H., Rosenberg, J. E., Hoimes, C. J., Petrylak, D. P., Milowsky, M. I., Mckay, R. R., Srinivas, S., Friedlander, T. W., Ramamurthy, C., Bilen, M., Burgess, E. F., Mar, N., Moon, H., Geynisman, D. M., George, S., Carret, A., Yu, Y., Guseva, M., Moreno, B., Flaig, T. W. LIPPINCOTT WILLIAMS & WILKINS. 2023
View details for Web of Science ID 001098050200528